JPH10332694A - Immunological measurement method - Google Patents
Immunological measurement methodInfo
- Publication number
- JPH10332694A JPH10332694A JP9161991A JP16199197A JPH10332694A JP H10332694 A JPH10332694 A JP H10332694A JP 9161991 A JP9161991 A JP 9161991A JP 16199197 A JP16199197 A JP 16199197A JP H10332694 A JPH10332694 A JP H10332694A
- Authority
- JP
- Japan
- Prior art keywords
- substance
- measured
- concentration
- sodium chloride
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Automatic Analysis And Handling Materials Therefor (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、免疫学的測定法に
関する。さらに詳しくは、被測定物質を正確に測定し、
被測定物質を希釈することや繰り返し測定することなし
に測定することができる免疫学的測定法に関する。TECHNICAL FIELD The present invention relates to an immunoassay. More specifically, the substance to be measured is accurately measured,
The present invention relates to an immunoassay method capable of measuring a substance to be measured without diluting the substance or without repeatedly measuring the substance.
【0002】[0002]
【従来の技術】免疫学的測定法において、被測定物質の
濃度が高くても被測定物質を希釈する繁雑な操作をする
ことなく測定する方法として、従来、被測定物質および
被測定物質と特異的に結合する物質を反応させる際の反
応液中のpHを6.0〜8.0の中性で塩化ナトリウム
濃度を20〜250g/Lとし、免疫反応を抑制させて
被測定物質を希釈なしで直接測定する方法が提案されて
いる[特開平09−089894]。2. Description of the Related Art In an immunoassay, a method for measuring a substance to be measured without a complicated operation of diluting the substance even when the concentration of the substance is high has been conventionally known as a method which is specific to a substance to be measured and a substance to be measured. The pH of the reaction solution when reacting a substance that is chemically bound is 6.0 to 8.0, the sodium chloride concentration is 20 to 250 g / L, the immune reaction is suppressed, and the substance to be measured is not diluted. A method for direct measurement has been proposed [JP-A-09-089894].
【0003】[0003]
【発明が解決しようとする課題】しかしながら、この測
定法で被測定物質を希釈なしで直接測定すると、被測定
物質の種類によっては測定値の再現精度が不十分である
ため、十分に正確な測定値を必要とする場合は、被測定
物質の繰り返し測定を行っていた。However, if the substance to be measured is directly measured without dilution by this measuring method, the accuracy of reproducibility of the measured value is insufficient depending on the kind of the substance to be measured, so that a sufficiently accurate measurement is performed. When a value was required, the substance to be measured was repeatedly measured.
【0004】[0004]
【課題を解決するための手段】本発明者らは、上記問題
を解決するため鋭意検討した結果、従来法を改善し、p
Hをより酸性またはアルカリ性の特定域に代えることに
より、高濃度の被測定物質でも意外にも大幅に精度が向
上することを見出し、本発明に到達した。すなわち本発
明は、下記およびの免疫学的測定法である。 被測定物質(A)および被測定物質と特異的に結合す
る物質(B)を免疫反応させる免疫学的測定法におい
て、免疫反応の際の液中のpHを3.5〜5.5にし、
かつ、塩化ナトリウム濃度を10〜250g/Lとする
ことを特徴とする免疫学的測定法。 被測定物質(A)および被測定物質と特異的に結合す
る物質(B)を免疫反応させる免疫学的測定法におい
て、免疫反応の際の液中のpHを9.0〜12.0に
し、かつ、塩化ナトリウム濃度を10〜250g/Lと
することを特徴とする免疫学的測定法。Means for Solving the Problems The present inventors have made intensive studies to solve the above-mentioned problems, and as a result, have improved the conventional method,
By replacing H with a more acidic or alkaline specific region, the present inventors have found that the accuracy of a substance to be measured is unexpectedly greatly improved, and the present invention has been achieved. That is, the present invention relates to the following immunological assay methods. In an immunoassay for immunoreacting a substance to be measured (A) and a substance (B) which specifically binds to the substance to be measured, the pH of the liquid at the time of the immune reaction is adjusted to 3.5 to 5.5,
An immunoassay wherein the sodium chloride concentration is 10 to 250 g / L. In an immunoassay for immunoreacting the substance to be measured (A) and the substance (B) which specifically binds to the substance to be measured, the pH in the liquid during the immune reaction is adjusted to 9.0 to 12.0, An immunoassay wherein the sodium chloride concentration is 10 to 250 g / L.
【0005】[0005]
【発明の実施の形態】本発明の方法では、(A)および
(B)を免疫反応させる際の液中のpHは、の方法で
は通常3.5〜5.5、好ましくは4.5〜5.5であ
り、の方法では通常9.0〜12.0、好ましくは1
0.0〜11.0である。BEST MODE FOR CARRYING OUT THE INVENTION In the method of the present invention, the pH of the solution used for the immunoreaction of (A) and (B) is usually 3.5 to 5.5, preferably 4.5 to 5.5 in the above method. In the above method, it is usually 9.0 to 12.0, preferably 1
0.0 to 11.0.
【0006】また、本発明の方法で、(A)および
(B)を免疫反応させる際の液中の塩化ナトリウム濃度
は、、の何れの方法においても通常10〜250g
/Lである。の方法の場合、液中の塩化ナトリウム濃
度は好ましくは上限を250g/Lとして、下式(1)
を満足する濃度である。 Y ≧ 5X−7.5 (1) [式中、Xは、免疫反応の際の液中のpHを示し、Y
は、液中の塩化ナトリウム濃度(g/L)を示す。] また、の方法の場合は、好ましくは上限を250g/
Lとして、下式(2)を満足する濃度である。 Y ≧ −3.33X+50 (2) [式中、Xは、免疫反応の際の液中のpHを示し、Y
は、液中の塩化ナトリウム濃度(g/L)を示す。] 、の何れの方法においても、液中の塩化ナトリウム
濃度は、更に好ましくは20〜250g/L、特に40
〜250g/Lである。[0006] In the method of the present invention, the concentration of sodium chloride in the liquid used for the immunoreaction of (A) and (B) is usually 10 to 250 g in any of the methods.
/ L. In the case of the method of (1), the upper limit of the sodium chloride concentration in the liquid is preferably set to 250 g / L, and the following formula (1)
Is a concentration that satisfies Y ≧ 5X−7.5 (1) [wherein X represents the pH of the solution during the immune reaction, and Y
Indicates the concentration of sodium chloride (g / L) in the liquid. In the case of the above method, the upper limit is preferably set to 250 g /
L is a density satisfying the following expression (2). Y ≧ −3.33X + 50 (2) [wherein X represents the pH of the solution during the immune reaction, and Y
Indicates the concentration of sodium chloride (g / L) in the liquid. ], The sodium chloride concentration in the liquid is more preferably 20 to 250 g / L, particularly preferably 40 to 250 g / L.
250250 g / L.
【0007】本発明の免疫学的測定法は、競合アッセイ
法、非競合アッセイ法などあらゆる免疫学的測定法に使
用できるが、(A)の濃度が高すぎると正確な測定値が
得られない場合が多々ある免疫学的測定法である非競合
アッセイ法に好ましく使用される。非競合アッセイ法と
は、少なくとも二つの同種または異種のエピトープを有
する(A)を測定する免疫学的測定法であり、検体中の
(A)の増加とともに、プロゾーン現象などが生じない
限り、(A)に結合する抗体や抗原などの特異反応物質
も増加する方法であり、その特異反応物質の増加にとも
なう濁度、散乱光、透過光、吸光度、放射能、発光、蛍
光などの測定信号値の変動を指標に測定する方法であ
る。Although the immunoassay of the present invention can be used for all immunoassays such as competitive assays and non-competitive assays, accurate measurements cannot be obtained if the concentration of (A) is too high. It is preferably used in non-competitive assays, which are often immunological assays. The non-competitive assay is an immunoassay in which (A) having at least two homologous or heterologous epitopes is measured. As long as (A) in the sample increases, unless a prozone phenomenon occurs, This is a method of increasing the number of specific reactants such as antibodies and antigens that bind to (A). Measurement signals such as turbidity, scattered light, transmitted light, absorbance, radioactivity, luminescence, and fluorescence accompanying the increase of the specific reactants This is a method of measuring the fluctuation of the value as an index.
【0008】また、本発明の免疫学的測定法は、非競合
アッセイ法の内、全体的な測定精度が向上する理由から
サンドイッチ法に好ましく使用される。サンドイッチ法
は、例えば、(A)と、(B)を不溶化担体に結合させ
た物質と、(B)を標識物に結合させた物質とを反応さ
せて得られる複合体における標識物量を測定することに
より、(A)を測定する。この複合体の形成反応は一段
反応で行っても二段反応で行ってもよい。二段反応の場
合、例えば、(A)と(B)を不溶化担体に結合させた
物質とを先ず反応させ、次いで(B)を標識物に結合さ
せた物質とを反応させて複合体とする。この二段反応の
場合は、一段目の免疫反応に本発明による方法をとる。
また、二段目の免疫反応にも本発明による方法をとった
方がより好ましい。[0008] The immunological assay of the present invention is preferably used in the sandwich method among non-competitive assays, because the overall measurement accuracy is improved. In the sandwich method, for example, the amount of a labeled substance in a complex obtained by reacting (A), a substance in which (B) is bound to an insolubilized carrier, and a substance in which (B) is bound to a labeled substance is measured. Thereby, (A) is measured. The complex formation reaction may be performed in a one-step reaction or a two-step reaction. In the case of a two-step reaction, for example, a substance in which (A) and (B) are bound to an insolubilizing carrier is first reacted, and then a substance in which (B) is bound to a label is reacted to form a complex. . In the case of this two-stage reaction, the method according to the present invention is used for the first-stage immune reaction.
It is more preferable to use the method according to the present invention also for the second stage immune reaction.
【0009】本発明の方法において使用することができ
る被測定物質(A)としては、(1)タンパク質関連項
目(AFP,CEA,CA19−9,CA125,CA
15−3,CA72−4,CA50,トロポニンI,ト
ロポニンT,ペプシノゲンI,ペプシノゲンII,PA,
PAP,SCC,NSE,IgE,特異IgE,β2−
マイクログロブリン(β2mと略),フェリチン,IA
P,C3,C4,C5,CRP,α2−MG,IgA,
IgM,IgG,IgE,IgD,CK−MB,CK−
MM,ミオグロビン,ミオシン,トランスフェリン,ア
ポリポタンパク,糖タンパク,アルブミン,マイクロア
ルブミン,ヘモグロブリン,グリコヘモグロビン,フル
クトサミン,HDL,LDL,RF,リンパ球サブセッ
ト,LE細胞,抗サイログロブリン抗体,抗マイクロゾ
ーム抗体,ASOなど)、(2)ホルモン関連項目(イ
ンシュリン,HCG,βHCG,成長ホルモン,TS
H,LH,FSH,プロラクチン,T3,T4,FT
3,FT4,TBG,C−ペプチド,T−Uptak
e,エストロゲン,HPL,E2,コルチゾール,プロ
ゲステロン,テストステロン,ソマトスタチンなど)、
(3)薬物関連項目(ジゴキシン,フェニトイン,フェ
ノバルビタール,テオフィリンなど)、並びに、(4)
数々の感染症関連項目(真菌,連鎖球菌,大腸菌,結核
菌,肝炎ウイルス,ヘルペスウイルス,エイズウイル
ス,カンジダ,マイコプラズマ,トキソプラズマ,梅
毒,マラリア原虫,赤痢アメ−バ−など)などのそのも
のおよびそれらの代謝物(ベロ毒素など)や抗体があげ
られる。これらのうち好ましくは、希釈を必要とする項
目(β2m,TBG,IAP,RF,LE細胞,抗サイ
ログロブリン抗体,抗マイクロゾーム抗体,C3,C4,
C5,CRP,α2−MG,IgA,IgM,IgG,I
gE,特異IgE,IgD,エストロゲン,HPL,ト
ランスフェリン,アルブミン,マイクロアルブミン,ヘ
モグロブリン,グリコヘモグロビン,フルクトサミン,
HDL,LDL,ASO,感染症関連項目そのものおよ
びその代謝物や抗体)などである。The analyte (A) that can be used in the method of the present invention includes (1) protein-related items (AFP, CEA, CA19-9, CA125, CA
15-3, CA72-4, CA50, troponin I, troponin T, pepsinogen I, pepsinogen II, PA,
PAP, SCC, NSE, IgE, specific IgE, β2-
Microglobulin (abbreviated as β2m), ferritin, IA
P, C3, C4, C5, CRP, α2-MG, IgA,
IgM, IgG, IgE, IgD, CK-MB, CK-
MM, myoglobin, myosin, transferrin, apolipoprotein, glycoprotein, albumin, microalbumin, hemoglobulin, glycohemoglobin, fructosamine, HDL, LDL, RF, lymphocyte subset, LE cell, anti-thyroglobulin antibody, anti-microsomal antibody, ASO ), (2) hormone-related items (insulin, HCG, βHCG, growth hormone, TS
H, LH, FSH, prolactin, T3, T4, FT
3, FT4, TBG, C-peptide, T-Uptak
e, estrogen, HPL, E2, cortisol, progesterone, testosterone, somatostatin, etc.),
(3) drug-related items (digoxin, phenytoin, phenobarbital, theophylline, etc.), and (4)
Numerous infectious disease related items (fungi, streptococci, Escherichia coli, Mycobacterium tuberculosis, hepatitis virus, herpes virus, AIDS virus, Candida, mycoplasma, toxoplasma, syphilis, malaria parasite, dysentery ameber, etc.) Metabolites (such as verotoxin) and antibodies. Of these, items requiring dilution (β2m, TBG, IAP, RF, LE cells, anti-thyroglobulin antibody, anti-microsomal antibody, C3, C4,
C5, CRP, α2-MG, IgA, IgM, IgG, I
gE, specific IgE, IgD, estrogen, HPL, transferrin, albumin, microalbumin, hemoglobulin, glycated hemoglobin, fructosamine,
HDL, LDL, ASO, infectious disease-related items themselves and their metabolites and antibodies).
【0010】被測定物質と特異的に結合する物質(B)
としては、被測定物質(A)と特異的に反応する抗体、
抗原などを用いることができる。例えば(A)がAFP
抗原なら(B)としては抗AFP抗体,(A)が抗HB
s抗体なら(B)としてはHBs抗原などである。ま
た、不溶化担体に結合させる場合の物質(B)および標
識物に結合させる場合の物質(B)の両物質は、被測定
物質と特異的に結合する物質でありさえすれば、両物質
が全く同一でなくても使用できる。例えば、モノクロー
ナル抗体とポリクローナル抗体の組合せや、ウサギ由来
の抗体とヤギ由来の抗体の組合せ等である。Substance (B) that specifically binds to the substance to be measured
As an antibody that specifically reacts with the analyte (A),
An antigen or the like can be used. For example, (A) is AFP
For antigen, (B) is anti-AFP antibody, (A) is anti-HB
For the s antibody, (B) is an HBs antigen or the like. In addition, the substance (B) in the case of binding to the insolubilized carrier and the substance (B) in the case of binding to the labeling substance are both substances as long as they are substances that specifically bind to the substance to be measured. They can be used even if they are not the same. For example, a combination of a monoclonal antibody and a polyclonal antibody, a combination of a rabbit-derived antibody and a goat-derived antibody, and the like.
【0011】不溶化担体としては、(1)ケイ酸質無機
担体[ガラス(ポ−ラス,ツヤ消しガラスなど),シリ
カゲル,ベンナイトなど]、(2)磁性体(磁性微粒子
など)、(3)有機担体(ポリエチレン,ポリプロピレ
ン,ポリスチレン,メチルペンテン樹脂,ポリカーボネ
ート,塩化ビニール樹脂,メタクリル樹脂,ABS樹
脂,エポキシ樹脂,フッ素樹脂,ナイロン,デキストラ
ン、ロ紙など)などいずれも公知の物質が使用される。
また、これらの不溶化担体は微粒子にされ懸濁の状態で
使用される場合もある。Examples of the insolubilizing carrier include (1) a siliceous inorganic carrier [glass (porous, frosted glass, etc.), silica gel, benite, etc.], (2) a magnetic substance (magnetic fine particles, etc.), and (3) an organic substance. Known materials are used for all carriers (polyethylene, polypropylene, polystyrene, methylpentene resin, polycarbonate, vinyl chloride resin, methacrylic resin, ABS resin, epoxy resin, fluororesin, nylon, dextran, paper, etc.).
In addition, these insolubilized carriers are sometimes used in the form of fine particles in suspension.
【0012】(B)を不溶化担体に結合させる方法とし
ては、(1)(B)をガラスに化学的に結合させる方法
(例えば、米国特許第4280992号明細書及び同第
3652761号明細書)や、(2)(B)をプラスチ
ックに物理吸着させる方法(例えば、イ−・エングバル
等;バイオシム・バイオフィズ・アクタ、251巻、4
27貢、1971年)等がある。さらに、(3)(B)
にビオチンを結合させたものと、不溶化担体にストレプ
トアビジンを結合させたものとから誘導して(B)を不
溶化担体に結合させる方法、(4)(B)に対する抗体
をあらかじめ不溶化担体に結合させておくことにより
(B)を不溶化担体に結合させる方法(例えば、特願平
04−174911号明細書)等、間接的に(B)を不
溶化担体に結合させる方法がある。As a method for bonding (B) to the insolubilized carrier, (1) a method for chemically bonding (B) to glass (for example, US Pat. Nos. 4,280,992 and 365,2761) and , (2) a method of physically adsorbing (B) to a plastic (for example, A. Engbal et al .; Biosim Biofiz Acta, Vol. 251, 4)
27 Tribute, 1971). Furthermore, (3) (B)
A method in which (B) is bound to an insolubilized carrier by deriving from a product in which biotin is bound to a biotin and a product in which streptavidin is bound to an insolubilized carrier; Thus, there is a method of indirectly binding (B) to the insolubilized carrier, such as a method of binding (B) to the insolubilized carrier (for example, Japanese Patent Application No. 04-174911).
【0013】標識物としては、アイソト−プ[I125な
ど]、酵素[ペルオキシダーゼ、アルカリフォスファタ
ーゼ、βガラクトシダーゼなど]、蛍光物質[ユーロピ
ウム誘導体など]、発光物質[アクリジウム誘導体な
ど]等いずれも公知の物質が使用される。Examples of the label include known substances such as isotope [I125 etc.], enzymes [Peroxidase, alkaline phosphatase, β-galactosidase etc.], fluorescent substances [Europium derivatives etc.], luminescent substances [Acridium derivatives etc.]. used.
【0014】(B)を標識物に結合させる方法として
は、(B)を標識物に結合させる方法(例えば、生化学
実験法15、東京化学同人、p.308〜330(19
93))がある。さらに、(B)にストレプトアビジン
を結合させ標識物にビオチンを結合させることにより
(B)を標識物に結合させる方法や、(B)に対する抗
体をあらかじめ標識物に結合させておくことにより
(B)を標識物に結合させる方法(例えば、特願昭63
−262479号明細書)等、間接的に(B)を標識物
に結合させる方法がある。As a method of binding (B) to a label, there is a method of binding (B) to a label (for example, Biochemical Experiment Method 15, Tokyo Kagaku Dojin, pp. 308-330 (19)
93)). Furthermore, a method of binding (B) to a label by binding streptavidin to (B) and binding to biotin, or a method of binding an antibody against (B) to a label beforehand (B) ) Is bound to a label (for example, Japanese Patent Application No. Sho 63).
-262479) and the method of indirectly binding (B) to a label.
【0015】本発明の方法を実施するにあたっては、測
定の正確性を更に向上させるため、測定時の被測定物質
や免疫反応用緩衝液の分注は、手動でなく機械により自
動的に行わせる方が好ましい。In carrying out the method of the present invention, in order to further improve the accuracy of the measurement, the substance to be measured and the buffer for the immunoreaction during the measurement are automatically dispensed by a machine instead of manually. Is more preferred.
【0016】[0016]
【実施例】以下、実施例により本発明をさらに説明する
が、本発明はこれに限定されるものではない。EXAMPLES The present invention will be further described with reference to the following examples, but the present invention is not limited to these examples.
【0017】免疫反応用緩衝液の調製;イオン交換水に
リン酸水素ナトリウムを5.15g/L、リン酸二水素
カリウムを0.764g/L、牛血清アルブミンを10
g/Lの濃度になる様添加し、さらに、塩化ナトリウム
濃度を 10g/L、 20g/L、 40g/L、
80g/L、160g/L、 250g/Lとな
るよう添加して合計6種類のpH調整前の緩衝液を作製
した。次に、〜のpH調整前の緩衝液の順序に、H
ClまたはNaOHを、適量添加して同一pHサンプル
を番号順に6種類ずつ調製する操作により、下記比較例
用、実施例用の緩衝液をそれぞれ作製した。 比較例用の緩衝液(pHが範囲外):pH2.5の免疫
反応用緩衝液a1〜a6、pH6.0の免疫反応用緩衝
液a7〜a12、pH7.2の免疫反応用緩衝液a13
〜a18、pH8.5の免疫反応用緩衝液a19〜a2
4、pH13.0の免疫反応用緩衝液a25〜a30、 実施例用の緩衝液(pHが範囲内):pH3.5の免疫
反応用緩衝液b1〜b6、pH4.5の免疫反応用緩衝
液b7〜b12、pH5.5の免疫反応用緩衝液b13
〜b18、pH9.0の免疫反応用緩衝液b19〜b2
4、pH10.0の免疫反応用緩衝液b25〜b30、
pH11.0の免疫反応用緩衝液b31〜b36、pH
12.0の免疫反応用緩衝液b37〜b42Preparation of a buffer for an immunoreaction; 5.15 g / L of sodium hydrogen phosphate, 0.764 g / L of potassium dihydrogen phosphate and 10% of bovine serum albumin in ion-exchanged water.
g / L, and the sodium chloride concentration was further increased to 10 g / L, 20 g / L, 40 g / L,
80 g / L, 160 g / L and 250 g / L were added to prepare a total of six kinds of buffer solutions before pH adjustment. Next, in order of the buffer solution before pH adjustment of
By the operation of adding an appropriate amount of Cl or NaOH to prepare six samples of the same pH in numerical order, buffer solutions for the following comparative examples and examples were prepared. Buffers for comparative examples (pH is out of range): immune reaction buffers a1 to a6 at pH 2.5, immune reaction buffers a7 to a12 at pH 6.0, and immune reaction buffer a13 at pH 7.2
To a18, pH 8.5 buffer solution for immune reaction a19 to a2
4, buffer solution for immune reaction a25 to a30 at pH 13.0, buffer solution for Examples (pH within range): buffer solution for immune reaction b1 to b6 at pH 3.5, buffer solution for immune reaction at pH 4.5 b7 to b12, an immune reaction buffer b13 having a pH of 5.5
To b18, pH 9.0 buffer for immune reaction b19 to b2
4, an immune reaction buffer b25 to b30 at pH 10.0,
Immune reaction buffers b31 to b36 at pH 11.0, pH
12.0 buffer buffer for immune reaction b37-b42
【0018】比較例1〜30及び実施例1〜42 β2
m免疫学的測定法 全自動酵素免疫分析装置OLYDAS−120(オリン
パス光学工業株式会社製)を用い、第一反応としてa1
〜a30、b1〜b42各々の0.3mLと、標準β2
m液またはβ2m含有検体の0.005mLと、抗β2
m抗体結合ガラスビーズ(以下G1とする)1個とを、
反応管中で37℃,16分間免疫反応させ、G1+β2
m複合体を形成させた。反応後、装置専用のB/F分離
液にて洗浄させB/F分離を行った。Comparative Examples 1 to 30 and Examples 1 to 42 β2
m Immunological Assay Using a fully automatic enzyme immunoassay analyzer OLYDAS-120 (manufactured by Olympus Optical Co., Ltd.), a1 was used as the first reaction.
0.3 mL of each of ~ a30, b1 ~ b42 and standard β2
0.005 mL of m-solution or β2m-containing specimen and anti-β2
m antibody-bound glass beads (hereinafter referred to as G1)
G1 + β2 was reacted in a reaction tube at 37 ° C. for 16 minutes.
m complex was formed. After the reaction, the mixture was washed with a B / F separation liquid dedicated to the device, and B / F separation was performed.
【0019】第二反応として、試験管中のG1+β2m
複合体1個に、ペルオキシダーゼ標識抗β2m抗体(以
下P1とする)を0.2mg/Lおよび牛血清アルブミ
ンを10g/Lおよび塩化ナトリウムを8.5g/L含
有する0.02Mのリン酸緩衝液(pH7.2)を0.
3mL分注させ、反応管中で37℃,16分間免疫反応
させ、G1+β2m+P1複合体を形成した。反応後、
装置専用のB/F分離液にて洗浄させB/F分離を行っ
た。As a second reaction, G1 + β2m in a test tube was used.
0.02 M phosphate buffer containing 0.2 mg / L of peroxidase-labeled anti-β2m antibody (hereinafter referred to as P1), 10 g / L of bovine serum albumin, and 8.5 g / L of sodium chloride per complex. (PH 7.2) to 0.
3 mL was dispensed and immunoreacted at 37 ° C. for 16 minutes in a reaction tube to form a G1 + β2m + P1 complex. After the reaction,
Washing was performed with a B / F separation liquid dedicated to the apparatus, and B / F separation was performed.
【0020】第三反応として、試験管中のG1+β2m
+P1複合体1個に、過酸化水素を0.1g/Lおよび
テトラメチルベンジジンを0.17g/L含有する酢酸
緩衝液を0.3mL分注させ、反応管中で37℃,1
5.5分間発色反応させ、反応後、0.7mlの脱イオ
ン水を混合させ、380nmで測光させた。As a third reaction, G1 + β2m in a test tube
+ P1 complex was dispensed with 0.3 mL of an acetate buffer containing 0.1 g / L of hydrogen peroxide and 0.17 g / L of tetramethylbenzidine, and the mixture was placed in a reaction tube at 37 ° C., 1
After a color development reaction for 5.5 minutes, 0.7 ml of deionized water was mixed after the reaction, and photometry was performed at 380 nm.
【0021】最後に、各標準β2m液の濃度値と測光値
をスプライン曲線で自動回帰させ、その検量線から、β
2m含有検体の測光値に対する濃度値を算出させた。Finally, the concentration value and photometric value of each standard β2m solution were automatically regressed with a spline curve, and β was determined from the calibration curve.
The concentration value for the photometric value of the 2m-containing specimen was calculated.
【0022】比較例31〜60及び実施例43〜84
TBG免疫学的測定法 全自動酵素免疫分析装置OLYDAS−120(オリン
パス光学工業株式会社製)を用い、第一反応として、a
1〜a30、b1〜b42各々の0.3mLと、標準T
BG液またはTBG含有検体の0.005mLと、抗T
BGm抗体結合ガラスビーズ(以下G2とする)1個と
を反応管中で37℃,16分間免疫反応させ、G2+T
BG複合体を形成させた。反応後、装置専用のB/F分
離液にて洗浄させB/F分離を行った。Comparative Examples 31 to 60 and Examples 43 to 84
TBG immunoassay Using a fully automatic enzyme immunoassay analyzer OLYDAS-120 (manufactured by Olympus Optical Co., Ltd.), a
0.3 mL of each of 1 to a30, b1 to b42, and standard T
0.005 mL of BG solution or TBG-containing sample and anti-T
A single BGm antibody-bound glass bead (hereinafter referred to as G2) was immunoreacted in a reaction tube at 37 ° C. for 16 minutes, and G2 + T
A BG complex was formed. After the reaction, the mixture was washed with a B / F separation liquid dedicated to the device, and B / F separation was performed.
【0023】第二反応として、試験管中のG2+TBG
複合体1個に、ペルオキシダーゼ標識抗TBG抗体(以
下P2とする)を0.4mg/Lおよび牛血清アルブミ
ンを10g/Lおよび塩化ナトリウムを8.5g/L含
有する0.02Mのリン酸緩衝液(pH7.2)を0.
3mL分注させ、反応管中で37℃,16分間免疫反応
させ、G2+TBG+P2複合体を形成した。反応後、
装置専用のB/F分離液にて洗浄させB/F分離を行っ
た。As a second reaction, G2 + TBG in a test tube was used.
0.02M phosphate buffer containing 0.4 mg / L of peroxidase-labeled anti-TBG antibody (hereinafter referred to as P2), 10 g / L of bovine serum albumin and 8.5 g / L of sodium chloride per complex. (PH 7.2) to 0.
3 mL was dispensed and immunoreacted at 37 ° C. for 16 minutes in a reaction tube to form a G2 + TBG + P2 complex. After the reaction,
Washing was performed with a B / F separation liquid dedicated to the apparatus, and B / F separation was performed.
【0024】第三反応として、試験管中のG2+TBG
+P2複合体1個に、過酸化水素を0.1g/Lおよび
テトラメチルベンジジンを0.17g/L含有する酢酸
緩衝液を0.3mL分注させ、反応管中で37℃,1
5.5分間発色反応させ、反応後、0.7mlの脱イオ
ン水を混合させ、380nmで測光させた。As a third reaction, G2 + TBG in a test tube
+ P2 complex was dispensed with 0.3 mL of an acetate buffer containing 0.1 g / L of hydrogen peroxide and 0.17 g / L of tetramethylbenzidine in a reaction tube at 37.degree.
After a color development reaction for 5.5 minutes, 0.7 ml of deionized water was mixed after the reaction, and photometry was performed at 380 nm.
【0025】最後に、各標準TBG液の濃度値と測光値
をスプライン曲線で自動回帰させ、その検量線から、T
BG含有検体の測光値に対する濃度値を算出させた。Finally, the concentration value and photometric value of each standard TBG solution are automatically regressed with a spline curve, and T
The concentration value for the photometric value of the BG-containing sample was calculated.
【0026】比較例1〜30及び実施例1〜42の評価 高濃度の被測定物質を正確に測定することができる免
疫学的測定法であることを確かめるため、比較例1〜3
0および実施例1〜42のβ2m免疫学的測定法で、2
0mg/Lのβ2m含有検体をそれぞれn=20で測定
し、同時再現性[測定値の標準偏差値/平均値×100
(%)]を求めた。その結果を表1に示す。Evaluation of Comparative Examples 1 to 30 and Examples 1 to 42 In order to confirm that the immunoassay method can accurately measure a high concentration of an analyte, Comparative Examples 1 to 3
0 and the β2m immunoassay of Examples 1-42
Each sample containing 0 mg / L β2m was measured at n = 20, and the simultaneous reproducibility [standard deviation of the measured value / mean value × 100]
(%)]. Table 1 shows the results.
【0027】[0027]
【表1】 [Table 1]
【0028】更に、比較例31〜60および実施例4
3〜84のTBG免疫学的測定法で、50mg/LのT
BG含有検体をそれぞれn=20で測定し、同時再現性
[測定値の標準偏差値/平均値×100(%)]を求め
た。その結果を表2に示す。Further, Comparative Examples 31 to 60 and Example 4
A TBG immunoassay of 3-84 with 50 mg / L T
The BG-containing samples were measured at n = 20, and the simultaneous reproducibility [standard deviation of the measured values / mean value × 100 (%)] was determined. Table 2 shows the results.
【0029】[0029]
【表2】 [Table 2]
【0030】評価結果の考察:表1および表2の結果か
ら、従来の方法では高濃度の被測定物質の測定値が正確
に得られないが、本発明によって得られる測定値の正確
性は飛躍的に向上していることが判る。即ち、本比較例
で、pH6.0〜8.5の中性付近の同時再現性の平均
は、β2m免疫学的測定法では20〜25%、TBG免
疫学的測定法では15〜16%であるが、本実施例での
pH範囲の同時再現性の平均は、β2m免疫学的測定法
で3〜5%、TBG免疫学的測定法で2〜4%である。
また、酸性上限値のpH5.5と範囲外のpH6、pH
8.5とアルカリ性下限値のpH9という若干のpHの
違いに臨界的な意義があることが確認される。さらに、
X,Yの関係が式(1),(2)の範囲外である場合
は、範囲内の同時再現性に比べて悪化していることも確
認される。Consideration of evaluation results: From the results of Tables 1 and 2, it is not possible to accurately obtain measured values of a high concentration of a substance to be measured by the conventional method, but the accuracy of the measured values obtained by the present invention is greatly improved. It can be seen that it has improved. That is, in this comparative example, the average of the simultaneous reproducibility near neutral pH 6.0 to 8.5 was 20 to 25% in the β2m immunoassay and 15 to 16% in the TBG immunoassay. However, the average reproducibility of the pH range in this example is 3-5% for the β2m immunoassay and 2-4% for the TBG immunoassay.
In addition, pH 5.5 of the acidic upper limit and pH 6 and pH out of the range.
It is confirmed that a slight difference between pH 8.5 and pH 9, which is the lower limit of alkalinity, has a critical significance. further,
When the relationship between X and Y is out of the range of Expressions (1) and (2), it is also confirmed that the simultaneous reproducibility in the range is worse.
【0031】[0031]
【発明の効果】従来は高濃度の被測定物質の測定値が十
分に正確に得られなかったため、被測定物質を希釈して
測定するか繰り返し測定して、測定値の正確性を高める
必要があったが、本発明によって、得られる測定値の正
確性が飛躍的に向上し、被測定物質を希釈して測定する
ことや繰り返し測定することなしで測定できるようにな
り、免疫学的測定法の測定操作上の簡便性も飛躍的に向
上する。According to the present invention, the measured value of a substance to be measured at a high concentration could not be obtained sufficiently accurately. Therefore, it is necessary to increase the accuracy of the measured value by diluting or measuring the substance to be measured or repeating the measurement. However, according to the present invention, the accuracy of the obtained measurement value is dramatically improved, and the measurement can be performed without diluting the measurement target substance or measuring it repeatedly, and the immunological measurement method The simplicity of the measurement operation is greatly improved.
Claims (4)
異的に結合する物質(B)を免疫反応させる免疫学的測
定法において、免疫反応の際の液中のpHを3.5〜
5.5にし、かつ、塩化ナトリウム濃度を10〜250
g/Lとすることを特徴とする免疫学的測定法。In an immunoassay for immunoreacting a substance to be measured (A) and a substance (B) which specifically binds to the substance to be measured, the pH of the solution during the immunoreaction is adjusted to 3.5 to 3.5.
5.5 and the sodium chloride concentration is 10-250
g / L.
度が下式(1)を満足する請求項1記載の免疫学的測定
法。 Y ≧ 5X−7.5 (1) [式中、Xは、免疫反応の際の液中のpHを示し、Y
は、液中の塩化ナトリウム濃度(g/L)を示す。]2. The method according to claim 1, wherein the concentration of sodium chloride in the solution at the time of the immune reaction satisfies the following formula (1). Y ≧ 5X−7.5 (1) [wherein X represents the pH of the solution during the immune reaction, and Y
Indicates the concentration of sodium chloride (g / L) in the liquid. ]
異的に結合する物質(B)を免疫反応させる免疫学的測
定法において、免疫反応の際の液中のpHを9.0〜1
2.0にし、かつ、塩化ナトリウム濃度を10〜250
g/Lとすることを特徴とする免疫学的測定法。3. An immunological assay for immunoreacting a substance to be measured (A) and a substance (B) which specifically binds to the substance to be measured, wherein the pH of the solution during the immunoreaction is 9.0 to 9.0. 1
2.0 and the sodium chloride concentration is 10-250.
g / L.
度が下式(2)を満足する請求項3記載の免疫学的測定
法。 Y ≧ −3.33X+50 (2) [式中、Xは、免疫反応の際の液中のpHを示し、Y
は、液中の塩化ナトリウム濃度(g/L)を示す。]4. The immunological assay method according to claim 3, wherein the concentration of sodium chloride in the solution at the time of the immune reaction satisfies the following formula (2). Y ≧ −3.33X + 50 (2) [wherein X represents the pH of the solution during the immune reaction, and Y
Indicates the concentration of sodium chloride (g / L) in the liquid. ]
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9161991A JPH10332694A (en) | 1997-06-03 | 1997-06-03 | Immunological measurement method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9161991A JPH10332694A (en) | 1997-06-03 | 1997-06-03 | Immunological measurement method |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH10332694A true JPH10332694A (en) | 1998-12-18 |
Family
ID=15745968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9161991A Pending JPH10332694A (en) | 1997-06-03 | 1997-06-03 | Immunological measurement method |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH10332694A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056682B2 (en) | 2001-12-27 | 2006-06-06 | Matsushita Electric Industrial Co., Ltd. | Immunoassay method and immunoassay reagent kit to be used therein |
US7202041B2 (en) | 2002-12-10 | 2007-04-10 | Matsushita Electric Industrial Co., Ltd. | Immunoreaction measurement method |
-
1997
- 1997-06-03 JP JP9161991A patent/JPH10332694A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056682B2 (en) | 2001-12-27 | 2006-06-06 | Matsushita Electric Industrial Co., Ltd. | Immunoassay method and immunoassay reagent kit to be used therein |
US7202041B2 (en) | 2002-12-10 | 2007-04-10 | Matsushita Electric Industrial Co., Ltd. | Immunoreaction measurement method |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4624930A (en) | Immunochemical process | |
US6835543B2 (en) | Step agglutination immunoassay | |
GB2084317A (en) | Antigen-linked competitive enzymeimmunoassay | |
EP0724156A1 (en) | Kit for immunologically assaying biological substance and assay process | |
JPH0618528A (en) | Method of analyzing particle strengthening agglutination in centrifugal analyzer by measuring brightness of turbidity | |
EP0190006B1 (en) | Methods of immunoassay | |
JP2019502110A (en) | Methods for reducing interference in immunoassays | |
KR920000057B1 (en) | Process and reagent for the determination of a specifically bindable substance | |
JPH0765998B2 (en) | Assay method and assay reagent for specifically binding substances | |
Price et al. | Light scattering immunoassay | |
EP0667529B1 (en) | Non-specific reaction suppressor for immunoassays | |
EP0101228B1 (en) | Particle agglutination assay of antigens | |
US4522922A (en) | Soluble assay | |
KR20140145121A (en) | Immunological analysis method and reagent | |
EP1801590B1 (en) | Method of assaying antigen and reagent therefor | |
JP2014228385A (en) | Immunity test method and immunity test kit | |
JPH10332694A (en) | Immunological measurement method | |
JP2001255325A (en) | Immunological assays and reagents | |
JPH02124462A (en) | Improved immunity measuring method | |
JP2684069B2 (en) | Method for measuring immunologically active substance and reagent therefor | |
JP3220546B2 (en) | Method for measuring antigen or antibody in the presence of immune complex | |
JPH0989894A (en) | Immunoassay | |
JP2001337092A (en) | Immunological measurement method and measurement reagent | |
JPH0727764A (en) | Antibody for immunological measurement blocking fc part, reagent for immunological measurement containing said antibody, immunological measuring method using said reagent for immunological measurement and block reagent blocking fc part | |
JPH0754322B2 (en) | Immunological assay and test reagents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071102 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081102 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 9 Free format text: PAYMENT UNTIL: 20091102 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Year of fee payment: 9 Free format text: PAYMENT UNTIL: 20091102 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 10 |
|
LAPS | Cancellation because of no payment of annual fees |